AGN-151597
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Retinitis Pigmentosa
Conditions
Advanced Retinitis Pigmentosa
Trial Timeline
Dec 14, 2015 → Oct 21, 2024
NCT ID
NCT02556736About AGN-151597
AGN-151597 is a phase 1/2 stage product being developed by AbbVie for Advanced Retinitis Pigmentosa. The current trial status is completed. This product is registered under clinical trial identifier NCT02556736. Target conditions include Advanced Retinitis Pigmentosa.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Retinitis Pigmentosa were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02556736 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced Retinitis Pigmentosa